• Molecular NameRamelteon
  • Synonymramelteon; TAK-375
  • Weight259.349
  • Drugbank_IDDB00980
  • ACS_NO196597-26-9
  • Show 2D model
  • LogP (experiment)2.536
  • LogP (predicted, AB/LogP v2.0)3.72
  • pkaN/A
  • LogD (pH=7, predicted)3.72
  • Solubility (experiment)Very slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-3.67
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.06
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds4
  • TPSA38.33
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyThe first in a new class of sleep agents that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), versus binding to GABA A receptors, such as with drugs like zolpidem, eszopiclone, and zaleplon.
  • Absorption_value84.0
  • Absorption (description)Rapid, total absorption is at least 84%.
  • Caco_2N/A
  • Bioavailability1.8
  • Protein binding82.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP1A2-mediated)
  • Half life1~2.6 h
  • ExcretionRenal (84%) and fecal (4%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most frequent adverse events leading to discontinuation in subjects receiving ROZEREM were somnolence (0.8%), dizziness (0.5%), nausea (0.3%), fatigue (0.3%), headache (0.3%), and insomnia (0.3%). [http://www.rxlist.com/cgi/generic/rozerem_ad.htm]
  • LD50 (rat)N/A
  • LD50 (mouse)N/A